3 3' 5-TRIIODO-L-THYRONINE SODIUM SALT& Chemical Properties

Melting point:

205 °C (dec.)(lit.)

storage temp. 

Store at -20°C

solubility 

DMF: 0.25 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 1 mg/ml

form 

A crystalline solid

color 

white to light pink

optical activity

[α]22/D +21.5°, c = 2 in 1 N HCl: ethanol, 1:2

InChI

1S/C15H12I3NO4.Na.H2O/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-4,6,12,20H,5,19H2,(H,21,22);;1H2/q;+1;/p-1/t12-;;/m0../s1

InChIKey

IRGJMZGKFAPCCR-LTCKWSDVSA-M

SMILES

O.[Na+].N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C([O-])=O

Safety Information

Safety Statements 

22-24/25

WGK Germany 

3

Storage Class

13 - Non Combustible Solids

3 3' 5-TRIIODO-L-THYRONINE SODIUM SALT& Usage And Synthesis

Description

3,3'',5-Triiodo-L-thyronine (T3) is a thyroid hormone. It is produced by 5''-monodeiodination of the prohormone thyroxine (T4) in various tissues, including liver and kidney. T3 is an agonist of thyroid hormone receptors TRα and TRβ (K_is = 2.3 nM for both) that modulates diverse biological properties, including metabolism, cardiac function, growth, and redox signaling. It also functions as an inhibitor of L-type amino acid transporter 1 (LAT1), inhibiting LAT1-mediated leucine uptake in HEK293 cells when used at a concentration of 10 μM.

Uses

Liothyronine sodium hydrate is an active form of thyroid hormone. Liothyronine sodium hydrate is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[1][2][3].

IC 50

Human Endogenous Metabolite

References

[1] Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94. DOI:10.1016/0304-3835(94)90274-7
[2] Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92. DOI:10.1006/bbrc.1993.2055
[3] Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 1;20(11):3622-34. DOI:10.1016/j.bmc.2012.03.056